Authors' Reply to Holko: "Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review"
Pharmacoecon Open
.
2017 Mar;1(1):71.
doi: 10.1007/s41669-017-0013-8.
Authors
Ilke Akpinar
1
,
Philip Jacobs
2
3
,
Dat T Tran
4
5
Affiliations
1
Department of Pediatric Surgery, Antalya Training and Research Hospital, Antalya, Turkey.
2
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
[email protected]
.
3
Institute of Health Economics, #1200-10405 Jasper Avenue, Edmonton, AB, T5J 3N4, Canada.
[email protected]
.
4
Institute of Health Economics, #1200-10405 Jasper Avenue, Edmonton, AB, T5J 3N4, Canada.
5
School of Public Health, University of Alberta, Edmonton, AB, Canada.
PMID:
29442301
PMCID:
PMC5689036
DOI:
10.1007/s41669-017-0013-8
No abstract available
Keywords:
Additional Consideration; Economic Evaluation; Health Outcome; Public Health; Study Drug.
Publication types
Letter